ALKBH5 and nonpapillary renal cell carcinoma: Downregulation of FTO (p < 0.01) and ALKBH5 (p < 0.01) was confirmed using RT-qPCR on ccRCC patients (n = 8) relative to controls (n = 8) from our cohort (Figure 4e).